All In Biotech

Free tool

FAERS Monitor: Myfembree

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214846 or its brand name (Myfembree, Estradiol, Norethindrone Acetate, Relugolix). Reports on generic versions are filed under their own applications.

Reports

1,516

Serious

162

11% of reports

Hospitalization

35

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • therapy interrupted472
  • heavy menstrual bleeding233
  • intermenstrual bleeding118
  • headache74
  • off label use72
  • hot flush70
  • alopecia68
  • menstruation irregular62
  • dysmenorrhoea60
  • nausea51
  • pain45
  • drug ineffective40
  • depression33
  • inappropriate schedule of product administration32
  • fatigue30

Reports by year received

View as table
YearReports
202166
2022241
2023542
2024481
2025108
202678

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,643 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
heavy menstrual bleedingSignal233368.8327.182,936
intermenstrual bleedingSignal118299.2251.134,053
therapy interruptedSignal47292.285.542,368
dysmenorrhoeaSignal6063.149.23,589
menstruation irregularSignal6232.225.21,841
hot flushSignal7012.910.3758
alopeciaSignal684.83.8203
inappropriate schedule of product administrationSignal322.51.727
depressionSignal332.01.416
headache741.61.318
off label use721.10.91
pain451.00.80
nausea510.90.71
fatigue300.50.412
drug ineffective400.40.333

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.